专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2001282073B2 Purification of HBV antigens for use in vaccines 未知
公开(公告)号：AU2001282073B2
公开(公告)日：2005-01-20
申请号：AU2001282073
申请日：2001-08-07
申请人： GLAXOSMITHKLINE BIOLOGICALS SA
发明人： OPSTEL OMER VAN , SERANTONI MICHELLE , SCHU PETER , HEYDER KOEN DE
IPC分类号： A61K39/29 , A61K38/00 , A61K39/00 , A61K39/295 , A61K39/39 , C07K1/14 , C07K14/02 , C07K014/02 , C07K001/36 , A61K039/29
摘要： The present invention relates to a method for the production of a hepatitis B antigen suitable for use in a vaccine, the method comprising purification of the antigen in the presence of cysteine, to vaccines comprising such antigens.

2. 发明申请

US20040156863A1 Stabilized HBc chimer particles as therapeutic vaccine for chronic hepatitis 失效
标题翻译：稳定的HBc嵌合体颗粒作为慢性肝炎的治疗性疫苗
公开(公告)号：US20040156863A1
公开(公告)日：2004-08-12
申请号：US10677074
申请日：2003-10-01
发明人： Mark Page , Martin Friede , Annette Elisabeth Schmidt , Detlef Stober
IPC分类号： A61K039/29
CPC分类号： A61K39/292 , A61K39/00 , A61K39/12 , A61K2039/5258 , A61K2039/545 , A61K2039/55555 , A61K2039/55561 , A61K2039/55566 , A61K2039/55572 , C07K14/005 , C07K2319/00 , C12N7/00 , C12N2730/10122 , C12N2730/10123 , Y02A50/407 , Y02A50/412 , Y02A50/414 , Y02A50/423 , Y02A50/476 , Y02A50/487 , Y02A50/489
摘要： A method of treating chronic hepatitis B is disclosed that comprises administering a T cell-stimulating amount of a vaccine to a patient. The vaccine comprises an immunogenic amount of chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (core) protein (HBc) that is engineered for both enhanced stability of self-assembled particles and the substantial absence of nucleic acid binding by those particles. The chimeric protein molecule can include one or more immunogenic epitopes peptide-bonded to one or more of the N-terminus, the immunogenic loop or the C-terminus of HBc. The enhanced stability of self-assembled particles is obtained by the presence of at least one heterologous cysteine residue near one or both of the amino-terminus and carboxy-terminus of the chimer molecule.
摘要翻译：公开了一种治疗慢性乙型肝炎的方法，其包括向患者施用T细胞刺激量的疫苗。疫苗包含免疫原性量的嵌合，羧基末端截短的乙型肝炎病毒核衣壳（核心）蛋白（核心）蛋白（HBc），其被设计用于增强自组装颗粒的稳定性和基本上不存在由这些颗粒结合的核酸。嵌合蛋白分子可以包括与HBc的一个或多个N末端，免疫原性环或C末端肽结合的一个或多个免疫原性表位。通过在嵌合体分子的氨基末端和羧基末端的一个或两个附近存在至少一个异源半胱氨酸残基获得自组装颗粒的增强的稳定性。

3. 发明申请

US20040151735A1 HCV compositions 审中-公开
标题翻译： HCV组合物
公开(公告)号：US20040151735A1
公开(公告)日：2004-08-05
申请号：US10703086
申请日：2003-11-07
申请人： INNOGENETICS
发明人： Geert Maertens , Erik Depla , Erik D'hondt
IPC分类号： A61K039/29 , C07K014/02
CPC分类号： C07K14/005 , A61K39/12 , A61K39/29 , A61K2039/525 , A61K2039/5258 , A61K2039/55505 , A61K2039/57 , C12N2770/24222 , C12N2770/24234
摘要： The invention relates to immunogenic and vaccine compositions useful in prophylactic and therapeutic treatment of HCV infection. More specifically, said compositions comprise a HCV envelope peptide and a HCV non-structural peptide.
摘要翻译：本发明涉及可用于预防和治疗HCV感染的免疫原性和疫苗组合物。更具体地，所述组合物包含HCV包膜肽和HCV非结构肽。

4. 发明申请

US20040141999A1 Antiviral and antiretroviral radioimmunomedicaments based on (alpha)-emitters and (beta)-emitters 审中-公开
标题翻译：基于（α） - 异基因和（β）抑制剂的抗病毒和抗逆转录病毒放射免疫疗法
公开(公告)号：US20040141999A1
公开(公告)日：2004-07-22
申请号：US10752563
申请日：2004-01-08
发明人： Wolfgang Bergter
IPC分类号： A61M036/14 , A61K051/00 , A61K039/395 , A61K039/29 , A61K039/00 , A61K039/21
CPC分类号： A61K51/1093 , A61K51/1006 , A61K51/1027
摘要： In a method of treating viral infections and of tumors induced thereby a radioimmunoconjugate (RIC) containing an immunologically effective component and a radioactive component is provided. The immunologically effective component contains a) a receptor molecule or a fragment thereof having affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells, or b) a fragment of the cellular receptor molecule modified by mutagenesis, the fragment having affinity to an epitope of the viral structural proteins expressed on the plasma membrane of infected cells. The radioactive component is an alpha emitter or a beta emitter. The therapeutical agent is effective against viral infections such as HIV, HBV, HCV, HDV, HTLV, CMV, EBV, or HHV8 infections.
摘要翻译：在治疗病毒感染和由此诱导的肿瘤的方法中，提供了含有免疫有效成分和放射性成分的放射免疫缀合物（RIC）。免疫有效成分含有a）对感染细胞的质膜上表达的病毒结构蛋白的表位具有亲和性的受体分子或其片段，或b）通过诱变修饰的细胞受体分子的片段，所述片段具有对感染细胞的质膜上表达的病毒结构蛋白的表位的亲和力。放射性成分是α发射体或β发射体。治疗剂对HIV，HBV，HCV，HDV，HTLV，CMV，EBV或HHV8感染等病毒感染有效。

5. 发明申请

US20040138122A1 Methods for treating viral infection using IL-28 and IL-29 有权
标题翻译：使用IL-28和IL-29治疗病毒感染的方法
公开(公告)号：US20040138122A1
公开(公告)日：2004-07-15
申请号：US10691923
申请日：2003-10-23
发明人： Kevin M. Klucher , Pallavur V. Sivakumar , Wayne R. Kindsvogel , Katherine E. Henderson
IPC分类号： A61K039/29
CPC分类号： A61K47/48215 , A61K38/20 , A61K38/21 , A61K47/60 , C07K14/54 , Y02A50/385 , Y02A50/393
摘要： IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
摘要翻译：已经显示IL-28A，IL-28B，IL-29及其某些突变体对病毒物种的光谱具有抗病毒活性。特别感兴趣的是在感染肝脏的病毒（例如乙型肝炎病毒和丙型肝炎病毒）上显示的抗病毒活性。此外，IL-28A，IL-28B，IL-29及其突变体在用干扰素治疗观察到的造血细胞上不表现出一些抗增殖活性。没有伴随干扰素治疗的免疫抑制作用，IL-28A，IL-28B和IL-29可用于治疗免疫功能低下的病毒感染患者。

6. 发明申请

US20040043036A1 Complex of Hepatitis B virus polymerase with p11 and method for controlling movement of the complex in HepG2 cell 失效
标题翻译：乙型肝炎病毒聚合酶与p11的复合物和控制HepG2细胞复合物运动的方法
公开(公告)号：US20040043036A1
公开(公告)日：2004-03-04
申请号：US10637602
申请日：2003-08-07
发明人： Ye Sun Han , Juhyun Choi , Dae-Sik Lim
IPC分类号： A61K039/29 , C12N009/22
CPC分类号： C07K14/005 , A61K38/00 , C07K14/4728 , C12N9/1276 , C12N2730/10122 , C12N2740/16222
摘要： Disclosed is a complex of the 11 kDa Ca2null binding protein of 11 and Hepatitis B virus polymerase (HBVPol) which moves to Promyelocytic Leukemia Nuclear Body (PMLNB). Furthermore, the present invention discloses a method for controlling movement of the HBVPol/p11 complex into the nucleus of HepG2 cell with adjusting of intracellular Ca2null ion concentration by administrating an agent for controlling calcium ion concentration in HepG2 cells.
摘要翻译：公开了11型11KDa Ca 2+结合蛋白和乙型肝炎病毒聚合酶（HBVPol）的复合物，其迁移到早幼粒细胞白血病核体（PMLNB）。此外，本发明公开了一种通过施用用于控制HepG2细胞中的钙离子浓度的试剂来控制HBVPol / p11复合体向HepG2细胞核移动的方法，调节细胞内Ca 2+离子浓度。

7. 发明申请

US20040018208A1 Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis B virus sequences 失效
标题翻译：杂种或嵌合多核苷酸，蛋白质和包含乙型肝炎病毒序列的组合物
公开(公告)号：US20040018208A1
公开(公告)日：2004-01-29
申请号：US10388337
申请日：2003-03-14
申请人： Institut Pasteur
发明人： Huseyin Firat , Francois Lemonnier , Pierre Langlade-Demoyen , Marie-Louise Michel , Andreas A. Suhrbier
IPC分类号： A61K039/29 , C07H021/04 , C12N007/00 , C12P021/02 , C12N005/06 , C07K014/02
CPC分类号： C07K14/005 , A61K39/0011 , A61K39/12 , A61K39/292 , A61K48/00 , A61K2039/5258 , A61K2039/57 , C07K2319/00 , C07K2319/40 , C12N2730/10122 , C12N2730/10134
摘要： H-2 class I negative, HLA-A2.1 transgeniic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1 restricted human tumor-associated CTL epitopes. A hierarchy was established among these epitopic peptides injected into mice in IFA which correlates globally with their capacity to bind and stabilize HLA-A2.1 molecules. Co-injection of a helper peptide enhanced most CTL responses. In contrast, classical HLA class I transgenic mice which still express their own class I molecules did not, in most cases, develop H.A.-A2.1-restricted CTL responses under the same experimental conditions. Different monoepitopic immunization strategies of acceptable clinical usage were compared in HHD mice. Recombinant Ty-virus-like particles, or DNA encoding epitopes fused to the hepatitis B virus middle envelope protein gave the best results. Using this latter approach and a melanoma-based polyepitope construct, CTL responses against five distinct epitopes could be elicited simultaneously in a single animal. Thus, HHD mice provide a versatile animal model for preclinical evaluation of peptide-based cancer immunotherapy.
摘要翻译：使用H-2 I型阴性，HLA-A2.1转基因HHD小鼠进行HLA-A2.1限制性人肿瘤相关CTL表位的免疫原性的比较评估。在IFA中注射到小鼠中的这些表位肽之间建立了等级关系，其全局与其结合和稳定HLA-A2.1分子的能力相关。辅助肽的共注射增强了大多数CTL应答。相比之下，仍然表达自己的I类分子的经典HLA I类转基因小鼠在大多数情况下并不在相同的实验条件下产生H.A.-A2.1限制性CTL应答。在HHD小鼠中比较了可接受的临床应用的不同单表位免疫策略。重组的Ty病毒样颗粒或编码与乙型肝炎病毒中膜包膜蛋白融合的表位的DNA得到最好的结果。使用后一种方法和基于黑素瘤的多表位构建体，可以在单个动物中同时诱导针对五种不同表位的CTL应答。因此，HHD小鼠为基于肽的癌症免疫治疗的临床前评估提供了通用的动物模型。

8. 发明申请

US20040001849A1 Antigen library immunization 审中-公开
标题翻译：抗原文库免疫
公开(公告)号：US20040001849A1
公开(公告)日：2004-01-01
申请号：US10383317
申请日：2003-03-07
申请人： Maxygen, Inc., a Delaware corporation
发明人： Juha Punnonen , Steven H. Bass , Robert Gerald Whalen , Russell Howard , Willem P.C. Stemmer
IPC分类号： A61K039/12 , A61K039/21 , A61K039/29 , A61K039/02 , C07K014/16 , C07K014/02 , C07K014/195
CPC分类号： C40B40/02 , A61K39/00 , A61K39/0011 , A61K39/015 , A61K39/0225 , A61K39/0258 , A61K39/0291 , A61K39/085 , A61K39/105 , A61K39/107 , A61K39/12 , A61K39/35 , A61K2039/53 , A61K2039/70 , C07K14/005 , C07K14/24 , C07K2319/02 , C07K2319/40 , C07K2319/74 , C12N15/1027 , C12N15/1034 , C12N15/1037 , C12N15/62 , C12N2710/16634 , C12N2730/10134 , C12N2740/16134 , C12N2760/12134 , C12N2770/24134 , C12N2770/24234 , C12N2770/36134 , Y02A50/474
摘要： This invention is directed to antigen library immunization, which provides methods for obtaining antigens having improved properties for therapeutic and other uses. The methods are useful for obtaining improved antigens that can induce an immune response against pathogens, cancer, and other conditions, as well as antigens that are effective in modulating allergy, inflammatory and autoimmune diseases.
摘要翻译：本发明涉及抗原文库免疫，其提供获得治疗和其它用途具有改进性质的抗原的方法。该方法可用于获得可诱导针对病原体，癌症和其它病症的免疫应答的改良抗原以及有效调节过敏，炎症和自身免疫性疾病的抗原。

9. 发明申请

US20030186224A1 CD4+ T-lymphocyte-specific hepatitis C virus-epitopes 失效
标题翻译： CD4 + T淋巴细胞特异性丙型肝炎病毒表位
公开(公告)号：US20030186224A1
公开(公告)日：2003-10-02
申请号：US10397411
申请日：2003-03-26
申请人： Immusystems GmbH
发明人： Jorn Tilman Gerlach , Helmut Diepolder
IPC分类号： C12Q001/70 , A61K039/29 , C07K014/02
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/53 , C12N2770/24222
摘要： The invention relates to Hepatitis C virus epitopes which are specific in relation to CD4null T lymphocytes, in addition to vaccinations which contain said epitopes.
摘要翻译：本发明涉及与CD4 + T淋巴细胞相关的特异性的丙型肝炎病毒表位，以及含有所述表位的疫苗接种。

10. 发明申请

US20030185857A1 Hepatitis B virus binding proteins and uses thereof 审中-公开
标题翻译：乙型肝炎病毒结合蛋白及其用途
公开(公告)号：US20030185857A1
公开(公告)日：2003-10-02
申请号：US10443923
申请日：2003-05-23
申请人： Yeda Research And Development Co. Ltd.
发明人： Yosef Shaul , Romi Zemel
IPC分类号： A61K038/16 , C12Q001/68 , A61K038/00 , C12P019/34 , A61K039/29
CPC分类号： C07K14/47 , A61K38/00
摘要： An isolated nucleic acid, a recombinant protein encoded thereby and uses thereof. The isolated nucleic acid including (a) a polynucleotide at least 60% identical to SEQ ID NOs:1, 3, 5 or portions thereof as determined using the Bestfit procedure of the DNA sequence analysis software package developed by the Genetic Computer Group (GCG) at the university of Wisconsin (gap creation penaltynull50, gap extension penaltynull3); (b) a polynucleotide encoding a polypeptide being at least 60% homologous with SEQ ID NOs:2, 4, 6 or portions thereof as determined using the Bestfit procedure of the DNA sequence analysis software package developed by the Genetic Computer Group (GCG) at the university of Wisconsin (gap creation penaltynull50, gap extension penaltynull3); or (c) a polynucleotide hybridizable with SEQ ID NOs:1, 3, 5 or portions thereof at 68null C. in 6nullSSC, 1% SDS, 5null Denharts, 10% dextran sulfate, 100 nullg/ml salmon sperm DNA, and 32p labeled probe and wash at 68null C. with 3nullSSC and 0.1% SDS.
摘要翻译：分离的核酸，由此编码的重组蛋白质及其用途。分离的核酸包括（a）使用Genetic Computer Group（GCG）开发的DNA序列分析软件包的Bestfit方法测定的与SEQ ID NO：1,3,5或其部分至少60％相同的多核苷酸，在威斯康星大学（差距创造罚球-50，差距延伸罚球-3）; （b）编码与SEQ ID NO：2,4,6或其部分至少60％同源的多肽的多核苷酸，其使用由Genetic Computer Group（GCG）开发的DNA序列分析软件包的Bestfit方法测定威斯康星大学（差距创造罚球-50，差距延伸罚球-3）; 或（c）可在SEQ ID NO：1,3,5或其部分在68℃下在6xSSC，1％SDS，5×Denharts，10％硫酸葡聚糖，100μg/ ml鲑鱼精子DNA中杂交的多核苷酸， 32> p标记的探针，并在68℃下用3×SSC和0.1％SDS洗涤。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式